BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27255944)

  • 1. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Bryce AH; Antonarakis ES
    Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
    Maughan BL; Antonarakis ES
    Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
    Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.
    Lu J; Lonergan PE; Nacusi LP; Wang L; Schmidt LJ; Sun Z; Van der Steen T; Boorjian SA; Kosari F; Vasmatzis G; Klee GG; Balk SP; Huang H; Wang C; Tindall DJ
    J Urol; 2015 Feb; 193(2):690-8. PubMed ID: 25132238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methods for androgen receptor splice variant-7 detection: Advances in studies].
    Li K; Fan GR; Chen CH; Wang ZP
    Zhonghua Nan Ke Xue; 2019 Nov; 25(11):1031-1035. PubMed ID: 32233239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Imamura Y; Sadar MD
    Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Splice variant AR-V7 : Is it time for its routine use as a predictive marker in prostate cancer?].
    Tsaur I; Becker C; Thelen P; Roos FC
    Urologe A; 2017 Sep; 56(9):1164-1167. PubMed ID: 28702748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Androgen receptor variants in prostate cancer].
    Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
    Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
    Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
    Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging data on androgen receptor splice variants in prostate cancer.
    Cao S; Zhan Y; Dong Y
    Endocr Relat Cancer; 2016 Dec; 23(12):T199-T210. PubMed ID: 27702752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The link between androgen receptor splice variants and castration-resistant prostate cancer.
    Sprenger CC; Plymate SR
    Horm Cancer; 2014 Aug; 5(4):207-17. PubMed ID: 24798453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor splice variants determine taxane sensitivity in prostate cancer.
    Thadani-Mulero M; Portella L; Sun S; Sung M; Matov A; Vessella RL; Corey E; Nanus DM; Plymate SR; Giannakakou P
    Cancer Res; 2014 Apr; 74(8):2270-2282. PubMed ID: 24556717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?
    Leibrand CR; Price DK; Figg WD
    Cancer Biol Ther; 2016 May; 17(5):467-9. PubMed ID: 26985596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.